Literature DB >> 45482

Possible changes in striatal and limbic cholinergic systems in schizophrenia.

P L McGeer, E G McGeer.   

Abstract

Enzymes concerned with neurotransmitter metabolism were measured postmortem in 50 regions from the brains of 11 chronic schizophrenics, 2 patients with senile dementia, 1 depressive, and 18 controls. Enzymes studied were tyrosine hydroxylase, dopa decarboxylase, glutamic decarboxylase, choline acetyltransferase (CAT), and acetylcholinesterase. The schizophrenic group had high CAT activities in the hippocampus, caudate, putamen, and nucleus accumbens; the other patients from the same hospital did not. A compensatory response to long- or short-term drug usage is considered, but correlations are hard to establish in the group studied. An alternative hypothesis proposes that the high levels are a compensatory response to defective cholinergic receptors in the affected areas. On this hypothesis, and by analogy with chorea, dopaminergic antagonists would act in schizophrenia by helping to reestablish cholinergic-dopaminergic balance.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 45482     DOI: 10.1001/archpsyc.1977.01770230061003

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  8 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 2.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

3.  Maximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.

Authors:  Karen E Stevens; Lijun Zheng; Kirsten L Floyd; Jerry A Stitzel
Journal:  Brain Res       Date:  2015-03-02       Impact factor: 3.252

4.  Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia.

Authors:  Jason R Tregellas; Jason Smucny; Josette G Harris; Ann Olincy; Keeran Maharajh; Eugene Kronberg; Lindsay C Eichman; Emma Lyons; Robert Freedman
Journal:  Am J Psychiatry       Date:  2014-05       Impact factor: 18.112

5.  Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects.

Authors:  S L Dewey; G S Smith; J Logan; J D Brodie; P Simkowitz; R R MacGregor; J S Fowler; N D Volkow; A P Wolf
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

Review 6.  Striatal cholinergic interneuron regulation and circuit effects.

Authors:  Sean Austin O Lim; Un Jung Kang; Daniel S McGehee
Journal:  Front Synaptic Neurosci       Date:  2014-10-21

7.  The effect of deficient muscarinic signaling on commonly reported biochemical effects in schizophrenia and convergence with genetic susceptibility loci in explaining symptom dimensions of psychosis.

Authors:  Costa Vakalopoulos
Journal:  Front Pharmacol       Date:  2014-12-15       Impact factor: 5.810

8.  Role of the central cholinergic system in the therapeutics of schizophrenia.

Authors:  Alvin V Terry
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.